LPA receptor antagonists and uses thereof
Granted: November 12, 2024
Patent Number:
12139474
The present disclosure relates generally to compounds that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of LPAR1, including fibrosis and liver diseases such as non-alcoholic steatohepatitis (NASH).
Tetracyclic compounds and uses thereof
Granted: October 22, 2024
Patent Number:
12122776
The present disclosure relates generally to certain tetracyclic compounds, pharmaceutical compositions comprising said compounds, and methods of making said compounds and pharmaceutical compositions. The compounds of the disclosure are useful in treating or preventing human immunodeficiency virus (HIV) infection.
Methods and intermediates for preparing therapeutic compounds
Granted: October 22, 2024
Patent Number:
12122765
The present disclosure relates to methods and intermediates useful for preparing a compound of formula I: or a co-crystal, solvate, salt or combination thereof.
IKAROS zinc finger family degraders and uses thereof
Granted: October 22, 2024
Patent Number:
12122764
The present disclosure relates to compounds that bind to and act as degraders of an IKAROS Family Zinc Finger (IKZF) protein, such as IKZF2 (Helios). The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding and degradation of an IKZF protein, such as IKZF2, including cancer.
Nucleoside phosphoramidate prodrugs
Granted: October 22, 2024
Patent Number:
12121529
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form thereof, represented by the following structure: Also disclosed are methods of treatment, uses, and processes for preparing each of which utilize the compound represented by formula I.
GLP-1R modulating compounds
Granted: October 22, 2024
Patent Number:
12121511
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition.
Phospholipid compounds and methods of making and using the same
Granted: October 15, 2024
Patent Number:
12116380
Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.
Prodrugs of phosphonamide nucleotide analogues and their pharmaceutical use
Granted: October 8, 2024
Patent Number:
12110305
Compounds, compositions, and method useful for treating a viral infection, such as human immunodeficiency virus (HIV) and/or hepatitis B virus (HBV) infection, are disclosed. In particular, prodrugs of phosphonamide nucleotide analogues and methods for their preparation and use as therapeutic or prophylactic agents are disclosed.
CD73 compounds
Granted: October 8, 2024
Patent Number:
12110294
The present disclosure provides pyrimidine dione compounds of Formula I and pharmaceutical compositions thereof, for treating cancer, including solid tumors either-used alone or in combination with other anti-cancer agents.
Methods of identifying HIV patients sensitive to therapy with GP120 V3 glycan-directed antibodies
Granted: October 1, 2024
Patent Number:
12102677
Provided are methods for identifying patient populations infected with HIV that can be targeted by antibodies that bind to HIV gp120 V3 glycan region.
Solid forms of FXR agonists
Granted: October 1, 2024
Patent Number:
12102625
Disclosed herein are novel solid forms of FXR agonists. The disclosure also relates to pharmaceutical compositions containing one or more of the solid forms disclosed herein, as well as methods of using the solid forms in the treatment of conditions mediated by FXR. The disclosure also relates to methods for obtaining such solid forms.
Bifunctional degraders of hematopoietic progenitor kinase and therapeutic uses thereof
Granted: September 17, 2024
Patent Number:
12091426
The present disclosure provides bifunctional compounds as HPK1 degraders via ubiquitin proteasome pathway, and method for treating diseases modulated by HPK1.
SARS-COV2 main protease inhibitors
Granted: September 17, 2024
Patent Number:
12091420
The present disclosure relates to compounds of Formula I: and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.
GLP-1R modulating compounds
Granted: September 17, 2024
Patent Number:
12091404
The present disclosure provides GLP-1R agonists, and compositions, methods, and kits thereof. Such compounds are generally useful for treating a GLP-1R mediated disease or condition in a human.
Antibodies selective for cells presenting EGFR at high density
Granted: September 10, 2024
Patent Number:
12084510
Herein described are antibodies to epidermal growth factor receptor (EGER) having an EGER binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.
Therapeutic compounds for HIV virus infection
Granted: September 10, 2024
Patent Number:
12084467
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.
HIV inhibitor compounds
Granted: September 10, 2024
Patent Number:
12084455
The invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of Formula I, processes for preparing compounds of Formula I, therapeutic methods for treating the proliferation of the HIV virus, treating AIDS or delaying the onset of AIDS symptoms in a mammal using compounds of Formula I.
Capsid inhibitors for the treatment of HIV
Granted: September 3, 2024
Patent Number:
12077537
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions disclosed herein may be used for the treatment or prevention of a Retroviridae viral infection, including an infection caused by the HIV virus.
Thienopyrrole compounds
Granted: August 27, 2024
Patent Number:
12070455
The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of an autoimmune disease and/or inflammatory condition, including systemic lupus erythematosus and cutaneous lupus erythematosus.
Thiadiazole IRAK4 inhibitors
Granted: August 13, 2024
Patent Number:
12060351
A compound of Formula (I): pharmaceutically acceptable salts thereof, deuterated analogs thereof, compositions thereof, and methods of treating disease using a compound thereof are disclosed.
